Literature DB >> 35177857

Influenza virus infection history shapes antibody responses to influenza vaccination.

Maria Auladell1, Hoang Vu Mai Phuong2, Le Thi Quynh Mai2, Yeu-Yang Tseng3,4, Louise Carolan3, Sam Wilks5, Pham Quang Thai2, David Price6,7, Nguyen Thanh Duong8, Nguyen Le Khang Hang2, Le Thi Thanh2, Nguyen Thi Hong Thuong9, Tran Thi Kieu Huong9, Nguyen Thi Ngoc Diep9, Vu Thi Ngoc Bich9, Arseniy Khvorov3,4, Luca Hensen1, Tran Nhu Duong2, Katherine Kedzierska1, Dang Duc Anh2, Heiman Wertheim9,10, Scott D Boyd11, Kim L Good-Jacobson12,13, Derek Smith5, Ian Barr3, Sheena Sullivan3,4, H Rogier van Doorn9,14, Annette Fox15,16,17.   

Abstract

Studies of successive vaccination suggest that immunological memory against past influenza viruses may limit responses to vaccines containing current strains. The impact of memory induced by prior infection is rarely considered and is difficult to ascertain, because infections are often subclinical. This study investigated influenza vaccination among adults from the Ha Nam cohort (Vietnam), who were purposefully selected to include 72 with and 28 without documented influenza A(H3N2) infection during the preceding 9 years (Australian New Zealand Clinical Trials Registry 12621000110886). The primary outcome was the effect of prior influenza A(H3N2) infection on hemagglutinin-inhibiting antibody responses induced by a locally available influenza vaccine administered in November 2016. Baseline and postvaccination sera were titrated against 40 influenza A(H3N2) strains spanning 1968-2018. At each time point (baseline, day 14 and day 280), geometric mean antibody titers against 2008-2018 strains were higher among participants with recent infection (34 (29-40), 187 (154-227) and 86 (72-103)) than among participants without recent infection (19 (17-22), 91 (64-130) and 38 (30-49)). On days 14 and 280, mean titer rises against 2014-2018 strains were 6.1-fold (5.0- to 7.4-fold) and 2.6-fold (2.2- to 3.1-fold) for participants with recent infection versus 4.8-fold (3.5- to 6.7-fold) and 1.9-fold (1.5- to 2.3-fold) for those without. One of 72 vaccinees with recent infection versus 4 of 28 without developed symptomatic A(H3N2) infection in the season after vaccination (P = 0.021). The range of A(H3N2) viruses recognized by vaccine-induced antibodies was associated with the prior infection strain. These results suggest that recall of immunological memory induced by prior infection enhances antibody responses to inactivated influenza vaccine and is important to attain protective antibody titers.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35177857     DOI: 10.1038/s41591-022-01690-w

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


  36 in total

Review 1.  Viral mutation rates.

Authors:  Rafael Sanjuán; Miguel R Nebot; Nicola Chirico; Louis M Mansky; Robert Belshaw
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

Review 2.  Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Authors:  Edward A Belongia; Danuta M Skowronski; Huong Q McLean; Catharine Chambers; Maria E Sundaram; Gaston De Serres
Journal:  Expert Rev Vaccines       Date:  2017-06-09       Impact factor: 5.217

3.  Influenza vaccine effectiveness in the community and the household.

Authors:  Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Benjamin J Cowling; Mark G Thompson; David K Shay; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2013-02-14       Impact factor: 9.079

Review 4.  Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.

Authors:  Edward A Belongia; Melissa D Simpson; Jennifer P King; Maria E Sundaram; Nicholas S Kelley; Michael T Osterholm; Huong Q McLean
Journal:  Lancet Infect Dis       Date:  2016-04-06       Impact factor: 25.071

Review 5.  The pathology of influenza virus infections.

Authors:  Jeffery K Taubenberger; David M Morens
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

6.  Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.

Authors:  Mark G Thompson; Allison Naleway; Alicia M Fry; Sarah Ball; Sarah M Spencer; Sue Reynolds; Sam Bozeman; Min Levine; Jacqueline M Katz; Manjusha Gaglani
Journal:  Vaccine       Date:  2016-02-10       Impact factor: 3.641

7.  Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons.

Authors:  Huong Q McLean; Mark G Thompson; Maria E Sundaram; Jennifer K Meece; David L McClure; Thomas C Friedrich; Edward A Belongia
Journal:  Clin Infect Dis       Date:  2014-09-29       Impact factor: 9.079

8.  Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility.

Authors:  Nicholas C Wu; Huibin Lv; Andrew J Thompson; Douglas C Wu; Wilson W S Ng; Rameshwar U Kadam; Chih-Wei Lin; Corwin M Nycholat; Ryan McBride; Weiwen Liang; James C Paulson; Chris K P Mok; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2019-05-28       Impact factor: 21.023

9.  A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Authors:  Danuta M Skowronski; Catharine Chambers; Suzana Sabaiduc; Gaston De Serres; Anne-Luise Winter; James A Dickinson; Mel Krajden; Jonathan B Gubbay; Steven J Drews; Christine Martineau; Alireza Eshaghi; Trijntje L Kwindt; Nathalie Bastien; Yan Li
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

10.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.

Authors:  Seth J Zost; Kaela Parkhouse; Megan E Gumina; Kangchon Kim; Sebastian Diaz Perez; Patrick C Wilson; John J Treanor; Andrea J Sant; Sarah Cobey; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

View more
  5 in total

Review 1.  Recent Advances in Plasma-Engineered Polymers for Biomarker-Based Viral Detection and Highly Multiplexed Analysis.

Authors:  Seyyed Mojtaba Mousavi; Seyyed Alireza Hashemi; Masoomeh Yari Kalashgrani; Ahmad Gholami; Navid Omidifar; Aziz Babapoor; Neralla Vijayakameswara Rao; Wei-Hung Chiang
Journal:  Biosensors (Basel)       Date:  2022-04-28

2.  Natural immunity helps overcome the age-related decline of SARS-CoV-2 vaccine immunogenicity.

Authors:  Chris P Verschoor; Laura Haynes
Journal:  Lancet Healthy Longev       Date:  2022-07-04

3.  Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses.

Authors:  Nina Urke Ertesvåg; Rebecca Jane Cox; Sarah Larteley Lartey; Kristin G-I Mohn; Karl Albert Brokstad; Mai-Chi Trieu
Journal:  NPJ Vaccines       Date:  2022-06-24       Impact factor: 9.399

4.  Severe acute respiratory syndrome coronavirus-2 vaccine-induced B cells aspire to long-lived connections: Tracking B-cell memory over time.

Authors:  Liam Kealy; Kim L Good-Jacobson
Journal:  Immunol Cell Biol       Date:  2022-04-16       Impact factor: 5.853

5.  Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses.

Authors:  Annette Fox; Louise Carolan; Vivian Leung; Hoang Vu Mai Phuong; Arseniy Khvorov; Maria Auladell; Yeu-Yang Tseng; Pham Quang Thai; Ian Barr; Kanta Subbarao; Le Thi Quynh Mai; H Rogier van Doorn; Sheena G Sullivan
Journal:  Viruses       Date:  2022-02-25       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.